Abstract
Stimulants are the first line of therapy for attention-deficit/hyperactivity disorder (ADHD) in children 6 years and older. Vyvanse is a long acting prodrug stimulant with well-established safety, tolerability and efficacy, when compared to other stimulants such as amphetamine and methylphenidate, and non-stimulants such as atomoxetine, guanfacine, and clonidine. Treatment related adverse events for stimulant drugs in all age groups have been reported in great detail, but there is limited data available in the literature regarding withdrawal symptoms from acute cessation or dose reduction in children.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
